Privium Fund Management B.V. Acquires 36,500 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Privium Fund Management B.V. lifted its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 14.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 289,804 shares of the biopharmaceutical company’s stock after purchasing an additional 36,500 shares during the quarter. Ultragenyx Pharmaceutical comprises approximately 1.6% of Privium Fund Management B.V.’s holdings, making the stock its 14th largest position. Privium Fund Management B.V.’s holdings in Ultragenyx Pharmaceutical were worth $8,717,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in RARE. Norges Bank bought a new stake in Ultragenyx Pharmaceutical in the second quarter worth $35,765,000. Frontier Capital Management Co. LLC purchased a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth about $19,106,000. Frazier Life Sciences Management L.P. boosted its stake in Ultragenyx Pharmaceutical by 49.3% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 983,715 shares of the biopharmaceutical company’s stock worth $35,768,000 after purchasing an additional 325,000 shares in the last quarter. Perceptive Advisors LLC purchased a new stake in Ultragenyx Pharmaceutical during the 2nd quarter valued at about $9,817,000. Finally, Bank of Nova Scotia bought a new stake in Ultragenyx Pharmaceutical during the 2nd quarter valued at about $8,799,000. Institutional investors own 97.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on RARE shares. Guggenheim dropped their target price on shares of Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating on the stock in a research note on Monday, January 5th. Wells Fargo & Company cut their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a research report on Tuesday, December 30th. Robert W. Baird cut their price target on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating for the company in a research note on Tuesday, December 30th. HC Wainwright cut their price objective on shares of Ultragenyx Pharmaceutical from $80.00 to $60.00 and set a “buy” rating for the company in a research report on Monday, January 5th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 21st. Sixteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus price target of $72.29.

Ultragenyx Pharmaceutical Trading Down 0.8%

NASDAQ RARE opened at $24.07 on Friday. Ultragenyx Pharmaceutical Inc. has a 12 month low of $18.41 and a 12 month high of $46.50. The stock’s 50 day moving average is $29.03 and its 200 day moving average is $29.96. The stock has a market cap of $2.32 billion, a PE ratio of -4.05 and a beta of 0.15.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.58). The company had revenue of $159.93 million during the quarter, compared to analysts’ expectations of $167.42 million. Ultragenyx Pharmaceutical had a negative return on equity of 414.17% and a negative net margin of 91.95%.Ultragenyx Pharmaceutical’s quarterly revenue was up 14.6% compared to the same quarter last year. During the same period last year, the firm posted ($1.40) EPS. On average, analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 3,081 shares of the stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $36.38, for a total transaction of $112,086.78. Following the completion of the transaction, the chief financial officer directly owned 95,146 shares in the company, valued at approximately $3,461,411.48. This represents a 3.14% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 5.50% of the company’s stock.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.